Trial Profile
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Controlled Release Paroxetine in the Treatment of Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Paroxetine (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 30 Mar 2010 Actual patient number (416) added as reported by ClinicalTrials.gov.
- 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.